Juvenescence raises $50 million in Series A, buys minority stake in AgeX
Firm invests $5 million in preclinical company developing drugs for age-related degenerative diseases.
Stem cell genes are helping inform this startup’s approach to cancer diagnostics
The same genes in stem cells and cancer cells are being expressed. OncoCyte is using this knowledge to develop a genetic diagnostic test.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BioTime commits $5M to spinoff working with Mount Sinai on big data-powered mhealth products
In a decidedly vague announcement Tuesday, regenerative medicine company BioTime’s subsidiary LifeMap Sciences said it’s spun off a mobile health company. LifeMap Solutions will “make health easier to measure and manage” by integrating data from mobile devices with other data like genetic profiles, lifestyle data and electronic records in a cloud-based system, BioTime said. It’s […]
Regenerative medicine startup Cell Targeting sold to BioTime
Cleveland stem cell technology developer Cell Targeting has sold its assets to BioTime, which specializes in stem cells for use in regenerative medicine and blood plasma volume expanders for use in surgery. The deal includes $250,000 in cash and about 262,000 shares of BioTime's common stock. Joseph Wagner, Cell Targeting's president, will become the chief executive at OncoCyte, a BioTime subsidiary.